Document is current
Any future updates will be listed below
-
Authors
Takahashi, Naoto https://orcid.org/0000-0002-6758-3787
Kikushige, Yoshikane
Nakamae, Hirohisa
Goto, Tatsunori
Tomita, Akihiro
Ichii, Michiko
Ito, Satoshi
Teshima, Takanori
Kirito, Keita
Ikezoe, Takayuki
Hatano, Kaoru
Tanaka, Hirokazu
Hiramoto, Nobuhiro
Osako, Ryohei
Aoki, Makoto
Malek, Kamel
Ueda, Yasunori
-
Funding
Funding for this research was provided by:
Novartis Pharma.
Akita University
- License Information
-
More Information
Article History
Received: 5 February 2025
Revised: 13 May 2025
Accepted: 18 May 2025
First Online: 26 May 2025
Declarations
:
: Naoto Takahashi: Grants/Contracts: Novartis Pharma, Asahi-Kasei Pharma Corporation and Otsuka Pharmaceutical (finance to the institution for scientific research); Honoraria: Pfizer, Novartis Pharma, and Otsuka Pharmaceutical (seminar presentations). Yoshikane Kikushige: Honoraria: Novartis Pharma (seminar presentation). Hirohisa Nakamae: Grants/Contracts: Novartis Pharma and Bristol Myers Squibb (grants); Consulting fees: Novartis Pharma (advisory consultation); Honoraria: Otsuka Pharmaceutical, Novartis Pharma, and Bristol Myers Squibb (lectures). Tatsunori Goto: no disclosures. Akihiro Tomita: Grants/Contracts: Chugai Pharmaceutical, Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharmaceutical, Nippon Kayaku Co., Ltd., Otsuka Pharmaceutical, Takeda Pharmaceutical, Mochida Pharmaceutical, Asahi Kasei Pharma Co., Taiho Pharmaceutical, and Shionogi & Co., Ltd. (grants); Honoraria: Chugai Pharmaceutical, Ono Pharmaceutical, AstraZeneca K.K, AbbVie GK, and Nippon Shinyaku Co., Ltd. (lectures). Michiko Ichii: Honoraria: Novartis Pharmaceuticals and Bristol Myers Squibb (lectures). Satoshi Ito: Honoraria: Johnson & Johnson. Takanori Teshima: Manuscript development: Novartis Pharma K.K. (funding, medical writing, article processing charges); Grants: Chugai Pharmaceutical Co., Ltd., Fuji Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., Nippon Kayaku Co., Ltd., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Sumitomo Pharma Co., Ltd., Asahi Kasei Pharma Corporation., Shionogi & Co., Ltd., and JCR Pharmaceuticals Co., Ltd. (research grants); Contracts: Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., LUCA Science Inc., Priothera SAS, and PharmaEssentia Corporation (clinical trial contacts); Consulting fees: Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., Meiji Seika Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Gilead Sciences Inc; Honoraria: Astellas Pharma Inc., AbbVie GK, AstraZeneca plc, Asahi Kasei Pharma Corporation, Gilead Sciences Inc., Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., Meiji Seika Pharma Co., Ltd., Novartis Pharma K.K., Bristol Myers Squibb K.K., Pfizer Inc., Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., and Nippon Kayaku Co., Ltd. (lectures); Leadership/Fiduciary role: Japanese Society of Hematology (Director), Japanese Society for Transplantation and Cellular Therapy (President), and Japan Society of Transfusion Medicine and Cell Therapy (Director). Keita Kirito: Honoraria: PharmaEssentia JAPAN, GlaxoSmithKline, and Takeda Pharmaceuticals (lectures). Takayuki Ikezoe: Honoraria: Novartis, Otsuka, Pfizer, and Amgen (educational events). Kaoru Hatano: no disclosures. Hirokazu Tanaka: no disclosures. Nobuhiro Hiramoto: no disclosures. Ryohei Osako: Employee of Novartis Pharma K.K. Makoto Aoki: Employee of Novartis Pharma K.K. Kamel Malek: Employee of Novartis AG and shareholder in Novartis. Yasunori Ueda: no disclosures.
